MAM
WhatsApp India supports small businesses to go digital; unveils #SMBSaathi Utsav
Mumbai: WhatsApp India on Tuesday unveiled #SMBSaathi Utsav, a programme aimed at supporting small businesses in adopting digital tools like the WhatsApp Business App to conduct their operations. The goal of this programme, which was launched in partnership with Josh Talks, is to educate and assist small businesses in realising their full potential through WhatsApp.
#SMBSaathi Utsav has kicked off with a pilot in Jaipur’s Johri Bazaar and Bapu Bazaar where 500+ small businesses are being trained on various aspects of running their business online.
India is home to approximately 63 million MSMEs (micro, small and medium enterprises) accounting for 30 per cent of the country’s GDP (gross domestic product) and employing over 110 million people at present. During the pandemic, these businesses were severely affected witnessing a 20-50 per cent decline in their overall earnings. One of the major reasons behind this fall was the lack of market access. To help these businesses revive from this downturn, WhatsApp launched the #SMBSaathi initiative earlier this year. The #SMBSaathi Utsav is the second phase of the #SMBSaathi campaign.
The initiative showcased inspiring stories of business owners across India who pivoted to digital ways of doing business during the pandemic. For many of these businesses, WhatsApp was their first digital gateway and an easier & more effective alternative to building and maintaining a website.
Businesses across sectors such as traditional arts and handicrafts, jewellery, fashion and apparel, food and beverage outlets and several others are being trained on using the various features of the WhatsApp Business App and are being guided on how they can market their product to the right audiences.
WhatsApp India head Abhijit Bose said, “We are excited to launch the #SMBSaathi and #SMBSaathi Utsav, programmes that are dedicated to India’s small business community. Small businesses are the backbone of our economy and technology has the potential to further boost their business. During the pandemic, we saw several small business owners thriving by using simple platforms such as WhatsApp Business App to stay connected with their customers. A small beauty salon in suburban Mumbai used WhatsApp Business App to keep her regular customers engaged through the lockdown, a dhaba owner in Gurgaon, is directly connecting with his customers using WhatsApp Business App thus driving an overall efficiency in his operations and reaching newer markets. Examples such as these are a testament to the fact that India’s small business owners have the ambition, passion and creativity to leverage simple and reliable technologies. We are committed to finding new ways of increasing awareness about simple digital tools for businesses to support and celebrate the spirit of entrepreneurship and innovation in India.”
Jaipur’s Rupam Jewellers owner Arvind Sharma said, “I always thought that taking my business online would be a difficult and tedious process. As small business owners, we have earlier focused only on the traditional ways of doing business. However, the pandemic taught us that it is important to innovate and find new ways of running our business on digital platforms as that is where the audience is today. WhatsApp plays a very important role in our everyday communication with our regular customers and now with my business digitally available on the WhatsApp Business App, it will become a lot easier to connect with newer customers and service them quickly.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
